APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiretroviral Agent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antiretroviral Agent Market Outlook and Growth Opportunities 2026

30 December 2025194 pages

Choose your research edition.

Industry ResearchAntiretroviral Agent Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiretroviral Agent Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Antiretroviral Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiretroviral Agent Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiretroviral Agent Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Antiretroviral Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antiretroviral Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiretroviral Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiretroviral Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antiretroviral Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antiretroviral Agent market include Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, Merck Sharp and Dohme, ViiV Healthcare, AbbVie, GlaxoSmithKline and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antiretroviral Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiretroviral Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiretroviral Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antiretroviral Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Antiretroviral Agent Segment by Company

Boehringer Ingelheim

Bristol-Myers Squibb

Genentech

Gilead Sciences

Merck Sharp and Dohme

ViiV Healthcare

AbbVie

GlaxoSmithKline

Pfizer

Mylan

Janssen Pharmaceuticals

Antiretroviral Agent Segment by Type

Fusion Inhibitors

Entry Inhibitors—CCR5 Co-Receptor Antagonist

Nucleoside Reverse Transcriptase Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Protease Inhibitors

HIV Integrase Strand Transfer Inhibitors

Others

Antiretroviral Agent Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Others

Antiretroviral Agent Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antiretroviral Agent status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antiretroviral Agent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antiretroviral Agent significant trends, drivers, influence factors in global and regions.

6. To analyze Antiretroviral Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiretroviral Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiretroviral Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiretroviral Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antiretroviral Agent market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiretroviral Agent industry.

Chapter 3: Detailed analysis of Antiretroviral Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antiretroviral Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antiretroviral Agent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antiretroviral Agent Industry Trends Table 2. Antiretroviral Agent Industry Drivers Table 3. Antiretroviral Agent Industry Opportunities and Challenges Table 4. Antiretroviral Agent Industry Restraints Table 5. Global Antiretroviral Agent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antiretroviral Agent Revenue Share by Company (2021-2026) Table 7. Global Antiretroviral Agent Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antiretroviral Agent Sales Volume Share by Company (2021-2026) Table 9. Global Antiretroviral Agent Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antiretroviral Agent Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antiretroviral Agent Key Company Manufacturing Base & Headquarters Table 12. Global Antiretroviral Agent Company, Product Type & Application Table 13. Global Antiretroviral Agent Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antiretroviral Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Fusion Inhibitors Table 18. Significant Companies of Entry Inhibitors—CCR5 Co-Receptor Antagonist Table 19. Significant Companies of Nucleoside Reverse Transcriptase Inhibitors Table 20. Significant Companies of Non-Nucleoside Reverse Transcriptase Inhibitors Table 21. Significant Companies of Protease Inhibitors Table 22. Significant Companies of HIV Integrase Strand Transfer Inhibitors Table 23. Significant Companies of Others Table 24. Global Antiretroviral Agent Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Antiretroviral Agent Sales Volume by Type (2021-2026) & (K Units) Table 26. Global Antiretroviral Agent Sales Volume by Type (2027-2032) & (K Units) Table 27. Global Antiretroviral Agent Sales Volume Share by Type (2021-2026) Table 28. Global Antiretroviral Agent Sales Volume Share by Type (2027-2032) Table 29. Global Antiretroviral Agent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Antiretroviral Agent Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Antiretroviral Agent Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Antiretroviral Agent Sales Value Share by Type (2021-2026) Table 33. Global Antiretroviral Agent Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Retail Pharmacies Table 35. Significant Companies of Online Pharmacies Table 36. Significant Companies of Hospital Pharmacies Table 37. Significant Companies of Others Table 38. Global Antiretroviral Agent Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Antiretroviral Agent Sales Volume by Application (2021-2026) & (K Units) Table 40. Global Antiretroviral Agent Sales Volume by Application (2027-2032) & (K Units) Table 41. Global Antiretroviral Agent Sales Volume Share by Application (2021-2026) Table 42. Global Antiretroviral Agent Sales Volume Share by Application (2027-2032) Table 43. Global Antiretroviral Agent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Antiretroviral Agent Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Antiretroviral Agent Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Antiretroviral Agent Sales Value Share by Application (2021-2026) Table 47. Global Antiretroviral Agent Sales Value Share by Application (2027-2032) Table 48. Global Antiretroviral Agent Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Antiretroviral Agent Sales by Region (2021-2026) & (K Units) Table 50. Global Antiretroviral Agent Sales Market Share by Region (2021-2026) Table 51. Global Antiretroviral Agent Sales by Region (2027-2032) & (K Units) Table 52. Global Antiretroviral Agent Sales Market Share by Region (2027-2032) Table 53. Global Antiretroviral Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Antiretroviral Agent Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Antiretroviral Agent Sales Value Share by Region (2021-2026) Table 56. Global Antiretroviral Agent Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Antiretroviral Agent Sales Value Share by Region (2027-2032) Table 58. Global Antiretroviral Agent Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Antiretroviral Agent Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Antiretroviral Agent Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global Antiretroviral Agent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Antiretroviral Agent Sales by Country (2021-2026) & (K Units) Table 63. Global Antiretroviral Agent Sales Market Share by Country (2021-2026) Table 64. Global Antiretroviral Agent Sales by Country (2027-2032) & (K Units) Table 65. Global Antiretroviral Agent Sales Market Share by Country (2027-2032) Table 66. Global Antiretroviral Agent Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Antiretroviral Agent Sales Value Market Share by Country (2021-2026) Table 68. Global Antiretroviral Agent Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Antiretroviral Agent Sales Value Market Share by Country (2027-2032) Table 70. Boehringer Ingelheim Company Information Table 71. Boehringer Ingelheim Business Overview Table 72. Boehringer Ingelheim Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Boehringer Ingelheim Antiretroviral Agent Product Portfolio Table 74. Boehringer Ingelheim Recent Development Table 75. Bristol-Myers Squibb Company Information Table 76. Bristol-Myers Squibb Business Overview Table 77. Bristol-Myers Squibb Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Bristol-Myers Squibb Antiretroviral Agent Product Portfolio Table 79. Bristol-Myers Squibb Recent Development Table 80. Genentech Company Information Table 81. Genentech Business Overview Table 82. Genentech Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Genentech Antiretroviral Agent Product Portfolio Table 84. Genentech Recent Development Table 85. Gilead Sciences Company Information Table 86. Gilead Sciences Business Overview Table 87. Gilead Sciences Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Gilead Sciences Antiretroviral Agent Product Portfolio Table 89. Gilead Sciences Recent Development Table 90. Merck Sharp and Dohme Company Information Table 91. Merck Sharp and Dohme Business Overview Table 92. Merck Sharp and Dohme Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Merck Sharp and Dohme Antiretroviral Agent Product Portfolio Table 94. Merck Sharp and Dohme Recent Development Table 95. ViiV Healthcare Company Information Table 96. ViiV Healthcare Business Overview Table 97. ViiV Healthcare Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. ViiV Healthcare Antiretroviral Agent Product Portfolio Table 99. ViiV Healthcare Recent Development Table 100. AbbVie Company Information Table 101. AbbVie Business Overview Table 102. AbbVie Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. AbbVie Antiretroviral Agent Product Portfolio Table 104. AbbVie Recent Development Table 105. GlaxoSmithKline Company Information Table 106. GlaxoSmithKline Business Overview Table 107. GlaxoSmithKline Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. GlaxoSmithKline Antiretroviral Agent Product Portfolio Table 109. GlaxoSmithKline Recent Development Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Pfizer Antiretroviral Agent Product Portfolio Table 114. Pfizer Recent Development Table 115. Mylan Company Information Table 116. Mylan Business Overview Table 117. Mylan Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Mylan Antiretroviral Agent Product Portfolio Table 119. Mylan Recent Development Table 120. Janssen Pharmaceuticals Company Information Table 121. Janssen Pharmaceuticals Business Overview Table 122. Janssen Pharmaceuticals Antiretroviral Agent Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Janssen Pharmaceuticals Antiretroviral Agent Product Portfolio Table 124. Janssen Pharmaceuticals Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Antiretroviral Agent Distributors List Table 128. Antiretroviral Agent Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Antiretroviral Agent Product Image Figure 2. Global Antiretroviral Agent Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiretroviral Agent Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antiretroviral Agent Sales (2021-2032) & (K Units) Figure 5. Global Antiretroviral Agent Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antiretroviral Agent Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Fusion Inhibitors Image Figure 10. Entry Inhibitors—CCR5 Co-Receptor Antagonist Image Figure 11. Nucleoside Reverse Transcriptase Inhibitors Image Figure 12. Non-Nucleoside Reverse Transcriptase Inhibitors Image Figure 13. Protease Inhibitors Image Figure 14. HIV Integrase Strand Transfer Inhibitors Image Figure 15. Others Image Figure 16. Global Antiretroviral Agent Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Antiretroviral Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Antiretroviral Agent Sales Volume Share by Type (2021-2032) Figure 19. Global Antiretroviral Agent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Antiretroviral Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Antiretroviral Agent Sales Value Share by Type (2021-2032) Figure 22. Retail Pharmacies Image Figure 23. Online Pharmacies Image Figure 24. Hospital Pharmacies Image Figure 25. Others Image Figure 26. Global Antiretroviral Agent Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Antiretroviral Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Antiretroviral Agent Sales Volume Share by Application (2021-2032) Figure 29. Global Antiretroviral Agent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Antiretroviral Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Antiretroviral Agent Sales Value Share by Application (2021-2032) Figure 32. Global Antiretroviral Agent Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global Antiretroviral Agent Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Antiretroviral Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Antiretroviral Agent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Antiretroviral Agent Sales Value (2021-2032) & (US$ Million) Figure 37. North America Antiretroviral Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Antiretroviral Agent Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Antiretroviral Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Antiretroviral Agent Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Antiretroviral Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Antiretroviral Agent Sales Value (2021-2032) & (US$ Million) Figure 43. South America Antiretroviral Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Antiretroviral Agent Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Antiretroviral Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Antiretroviral Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Antiretroviral Agent Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Antiretroviral Agent Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Fusion Inhibitors
  • Entry Inhibitors—CCR5 Co-Receptor Antagonist
  • Nucleoside Reverse Transcriptase Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Others
Companies covered
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Genentech
  • Gilead Sciences
  • Merck Sharp and Dohme
  • ViiV Healthcare
  • AbbVie
  • GlaxoSmithKline
  • Pfizer
  • Mylan
  • Janssen Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antiretroviral Agent Sales Value (2021-2032)
  4. 1.2.2 Global Antiretroviral Agent Sales Volume (2021-2032)
  5. 1.2.3 Global Antiretroviral Agent Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antiretroviral Agent Market Dynamics
  1. 2.1 Antiretroviral Agent Industry Trends
  2. 2.2 Antiretroviral Agent Industry Drivers
  3. 2.3 Antiretroviral Agent Industry Opportunities and Challenges
  4. 2.4 Antiretroviral Agent Industry Restraints
3 Antiretroviral Agent Market by Company
  1. 3.1 Global Antiretroviral Agent Company Revenue Ranking in 2025
  2. 3.2 Global Antiretroviral Agent Revenue by Company (2021-2026)
  3. 3.3 Global Antiretroviral Agent Sales Volume by Company (2021-2026)
  4. 3.4 Global Antiretroviral Agent Average Price by Company (2021-2026)
  5. 3.5 Global Antiretroviral Agent Company Ranking (2024-2026)
  6. 3.6 Global Antiretroviral Agent Company Manufacturing Base and Headquarters
  7. 3.7 Global Antiretroviral Agent Company Product Type and Application
  8. 3.8 Global Antiretroviral Agent Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antiretroviral Agent Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antiretroviral Agent Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antiretroviral Agent Market by Type
  1. 4.1 Antiretroviral Agent Type Introduction
  2. 4.1.1 Fusion Inhibitors
  3. 4.1.2 Entry Inhibitors—CCR5 Co-Receptor Antagonist
  4. 4.1.3 Nucleoside Reverse Transcriptase Inhibitors
  5. 4.1.4 Non-Nucleoside Reverse Transcriptase Inhibitors
  6. 4.1.5 Protease Inhibitors
  7. 4.1.6 HIV Integrase Strand Transfer Inhibitors
  8. 4.1.7 Others
  9. 4.2 Global Antiretroviral Agent Sales Volume by Type
  10. 4.2.1 Global Antiretroviral Agent Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Antiretroviral Agent Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Antiretroviral Agent Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Antiretroviral Agent Sales Value by Type
  14. 4.3.1 Global Antiretroviral Agent Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Antiretroviral Agent Sales Value by Type (2021-2032)
  16. 4.3.3 Global Antiretroviral Agent Sales Value Share by Type (2021-2032)
5 Antiretroviral Agent Market by Application
  1. 5.1 Antiretroviral Agent Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.1.4 Others
  6. 5.2 Global Antiretroviral Agent Sales Volume by Application
  7. 5.2.1 Global Antiretroviral Agent Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antiretroviral Agent Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Antiretroviral Agent Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Antiretroviral Agent Sales Value by Application
  11. 5.3.1 Global Antiretroviral Agent Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Antiretroviral Agent Sales Value by Application (2021-2032)
  13. 5.3.3 Global Antiretroviral Agent Sales Value Share by Application (2021-2032)
6 Antiretroviral Agent Regional Sales and Value Analysis
  1. 6.1 Global Antiretroviral Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiretroviral Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Antiretroviral Agent Sales by Region: 2021-2026
  4. 6.2.2 Global Antiretroviral Agent Sales by Region (2027-2032)
  5. 6.3 Global Antiretroviral Agent Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antiretroviral Agent Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antiretroviral Agent Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antiretroviral Agent Sales Value by Region (2027-2032)
  9. 6.5 Global Antiretroviral Agent Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antiretroviral Agent Sales Value (2021-2032)
  12. 6.6.2 North America Antiretroviral Agent Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antiretroviral Agent Sales Value (2021-2032)
  15. 6.7.2 Europe Antiretroviral Agent Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antiretroviral Agent Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antiretroviral Agent Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antiretroviral Agent Sales Value (2021-2032)
  21. 6.9.2 South America Antiretroviral Agent Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antiretroviral Agent Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antiretroviral Agent Sales Value Share by Country, 2025 VS 2032
7 Antiretroviral Agent Country-level Sales and Value Analysis
  1. 7.1 Global Antiretroviral Agent Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antiretroviral Agent Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antiretroviral Agent Sales by Country (2021-2032)
  4. 7.3.1 Global Antiretroviral Agent Sales by Country (2021-2026)
  5. 7.3.2 Global Antiretroviral Agent Sales by Country (2027-2032)
  6. 7.4 Global Antiretroviral Agent Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antiretroviral Agent Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antiretroviral Agent Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antiretroviral Agent Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antiretroviral Agent Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antiretroviral Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Antiretroviral Agent Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Antiretroviral Agent Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Genentech
  14. 8.3.1 Genentech Company Information
  15. 8.3.2 Genentech Business Overview
  16. 8.3.3 Genentech Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Genentech Antiretroviral Agent Product Portfolio
  18. 8.3.5 Genentech Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Antiretroviral Agent Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Merck Sharp and Dohme
  26. 8.5.1 Merck Sharp and Dohme Company Information
  27. 8.5.2 Merck Sharp and Dohme Business Overview
  28. 8.5.3 Merck Sharp and Dohme Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Sharp and Dohme Antiretroviral Agent Product Portfolio
  30. 8.5.5 Merck Sharp and Dohme Recent Developments
  31. 8.6 ViiV Healthcare
  32. 8.6.1 ViiV Healthcare Company Information
  33. 8.6.2 ViiV Healthcare Business Overview
  34. 8.6.3 ViiV Healthcare Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 ViiV Healthcare Antiretroviral Agent Product Portfolio
  36. 8.6.5 ViiV Healthcare Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Antiretroviral Agent Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Antiretroviral Agent Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Antiretroviral Agent Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Mylan
  56. 8.10.1 Mylan Company Information
  57. 8.10.2 Mylan Business Overview
  58. 8.10.3 Mylan Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Mylan Antiretroviral Agent Product Portfolio
  60. 8.10.5 Mylan Recent Developments
  61. 8.11 Janssen Pharmaceuticals
  62. 8.11.1 Janssen Pharmaceuticals Company Information
  63. 8.11.2 Janssen Pharmaceuticals Business Overview
  64. 8.11.3 Janssen Pharmaceuticals Antiretroviral Agent Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Janssen Pharmaceuticals Antiretroviral Agent Product Portfolio
  66. 8.11.5 Janssen Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antiretroviral Agent Value Chain Analysis
  2. 9.1.1 Antiretroviral Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antiretroviral Agent Sales Mode & Process
  6. 9.2 Antiretroviral Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antiretroviral Agent Distributors
  9. 9.2.3 Antiretroviral Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst